Navigation Links
Electrical Brain Stimulation Plus Drug Fights Depression: Study

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Feb. 6 (HealthDay News) -- Treating major depression safely and affordably is a challenge. Now, Brazilian researchers have found that two techniques often used individually produce better results when used together.

The researchers paired the antidepressant Zoloft (sertraline) and a type of noninvasive brain stimulation called transcranial direct current stimulation (tDCS) to treat people with moderate to severe symptoms of major depression.

Transcranial direct current stimulation appears to be just as effective a treatment as Zoloft, but the two together are even more effective, said lead researcher Dr. Andre Russowsky Brunoni, from the Clinical Research Center at University Hospital of the University of Sao Paulo.

This painless treatment uses a low-intensity electrical current to stimulate specific parts of the brain. Previously, it has been tested for various conditions, such as stroke, anxiety, pain and Parkinson's disease, the researchers said.

Dr. Sarah Hollingsworth Lisanby, chair of the department of psychiatry and behavioral sciences at Duke University School of Medicine, is enthusiastic about the findings.

Lisanby said the advent of technologies such as noninvasive brain stimulation is "one of the exciting new developments" in treating depression.

Transcranial direct current stimulation is one of a family of approaches that uses electrical or magnetic fields to stimulate the brain to alter brain function, she said.

"These techniques offer great promise for people with depression, because we know, unfortunately, medications aren't always effective, and psychotherapy isn't always effective, so having effective alternatives is important," Lisanby said.

She noted the current study's two-pronged approach addresses both aspects of brain action. The drug affects the chemical aspects of brain function, while the electrical stimulation targets the brain's electrical activity.

"Because the brain is an electro/chemical organ, using both electrical and chemical approaches to treat it makes intuitive sense," she said.

For the report, published online Feb. 6 in JAMA Psychiatry, Brunoni's team divided 120 patients with major depression who had never taken antidepressants to take Zoloft or an inactive placebo every day with or without electrical brain stimulation, or with sham stimulation.

After six weeks of treatment, Brunoni's group found depression significantly improved among patients receiving Zoloft or electrical brain stimulation. However, the biggest gain was seen in those who received both therapies. To gauge improvement, the researchers used the Montgomery-Asberg depression rating scale.

Overall, the patients received 12 half-hour brain stimulation sessions over six weeks.

Side effects from brain stimulation usually are mild and include itching, scratching and redness on the stimulated area, Brunoni said.

However, the combination treatment was associated with more cases of mania after treatment, he said. "Although we could not rule out whether this association was spurious, other studies should investigate this issue," Brunoni said.

Brain stimulation alone could be useful for patients who can't take psychiatric drugs, he said. And the devices that deliver the treatment are relatively affordable, the authors noted.

Brunoni hopes this study will stimulate additional trials using this approach. "If other studies are also positive, tDCS might be a clinical therapy in the future," he said.

People suffering from major depression usually need lifetime treatment, he added. If these study results pan out, this could mean taking antidepressants daily and undergoing weekly sessions of brain stimulation for optimal relief, he said.

Another expert said brain stimulation looks "very promising" as an emerging new treatment for depression. "The safety profile is excellent," said Dr. Colleen Loo, a professor in the School of Psychiatry at the University of New South Wales in Australia. "It is a very mild form of brain stimulation, no risk of seizures, does not impair thinking and may in fact improve thinking," she said.

Currently, tDCS is not approved by the U.S. Food and Drug Administration to treat any condition, Lisanby said.

However, another noninvasive, brain-stimulating technique is FDA-approved and clinically available, she said. That technique -- called transcranial magnetic stimulation (tMS) -- uses a magnetic field to induce electrical changes within the brain.

Other potential treatments for depression that are undergoing testing include vagus nerve stimulation (this is the nerve running from the brain to deep in the belly) and deep brain stimulation, she said.

More information

For more information on depression, visit the U.S. National Institute of Mental Health.

SOURCES: Andre Russowsky Brunoni, M.D., Ph.D., Center for Clinical Research, University Hospital, University of Sao Paulo, Brazil; Sarah Hollingsworth Lisanby, M.D., Lawrence C. Katz Professor and Chair, department of psychiatry and behavioral sciences, Duke University, Durham, N.C.; Colleen Loo, M.D., professor, School of Psychiatry, University of New South Wales, Australia; Feb. 6, 2013, JAMA Psychiatry, online

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. After 100 years, understanding the electrical role of dendritic spines
2. New electrically-conductive polymer nanoparticles can generate heat to kill colorectal cancer cells
3. Electrical characteristics of printed products determined in a snap
4. Electrical Brain Stimulation Curbs Epileptic Seizures in Rats
5. Unprecedented accuracy in locating brain electrical activity with new device
6. Electrical brain stimulation can alleviate swallowing disorders after stroke
7. Study of brain cooling and clot-busting drug therapy for stroke receives FDA OK to expand
8. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
9. Stroke damage in mice overcome by training that rewires brain centers
10. The zebrafish revealed a central regulator for the development of the brain histamine system
11. A Good Mood May Boost Seniors Brain Power
Post Your Comments:
Related Image:
Electrical Brain Stimulation Plus Drug Fights Depression: Study 
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a ... ™ attracts volunteers together who want to combine talents and resources to help ... in the process. The non-profit launched its first major fundraiser on November 6, ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 , ... ... Thanksgiving through Christmas Eve on several models of traditional and far-infrared saunas. ... . Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only ...
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... , ... November 26, 2015 , ... ... Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public ... in Nairobi (UNON) for the opening of the 5th African Network for Drugs ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
Breaking Medicine Technology: